Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I expect a lot of news in the next weeks.
Ok. Two other questions: is this something that American citizens are waiting for and is this something that distributors are waiting for?
Did they have put a deadline bringing this into the market?
Green close. CSKH is debt free also. More news will be coming.
We will see audited results early in the fourth quarter. That could be today, next week, or next month.
You should have a look at the front page of their website: it is very interesting:
http://www.amsteminc.com/
Fulfilling the Worldwide Promise of Stem Cells
AmStem is a new biotechnology company based in San Francisco, California. It has many unique advantages over other stem cell companies; representing a groundbreaking investment opportunity:
1. AmStem controls one of the largest, Asian Cord Blood Banks accredited in the world (more than twice as large as its nearest competitor). Umbilical cord blood is a very popular source of stem cells for research and treatment.
2. AmStem is the exclusive distributor of a Stem Cell derived Facial Cream that is fully developed, attractively packaged, and ready for the $21 Billion world market.
3. AmStem oversees Clinical Trials currently conducted in Korea that are using umbilical acquired stem cells derived from cord blood to treat various diseases.
4. AmStem controls the Patents for the methods used to create the above lines of business, and has many other patents pending.
AmStem Developmental Plans
In September 2009, Stem Cell Therapy International Inc. (OTC: AMST) executed a Reorganization and Stock Purchase Agreement with Histostem Co., Ltd. a Korean company, which will result in one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity. Following the execution of the Agreement, AmStem – a wholly-owned subsidiary of AMST – will be managing the U.S. operations of Histostem.
AmStem will develop a three-pronged, international strategic platform by using the expertise of its Management Team to improve upon the successes of Histostem:
Join the “Cosmeceuticals” Boom
AmStem is making connections to partner with a major cosmetic distributor or department store brand, to enter the booming “cosmeceutical” market with one of the newest and most exciting stem cell derived beauty products.
The development of other products by Histostem’s accomplished team of scientists, and/or acquisition of similar, supporting lines of products from other companies is a major objective.
High-Tech Cord Blood Banking
1. AmStem will make inroads to link up Histostem’s vast repository of genetically desirable Cord Blood Units (CBUs) with other international networks that provide HLA-typed cord blood samples directly to physicians for the off-label treatment of their patients. A new European Patent was recently awarded to support this.
2. These high-quality CBUs, monitored and quality-controlled by a state-of-the-art cryopreservation system, will also be made available to researchers at major hospitals and universities around the world. Two recent hospitals have recently opened the gateway to the vast Chinese medical market by awarding a contract to Histostem.
3. Histostem was recently granted a new US Patent for their proprietary method on deriving the maximum number of viable stem cells from a frozen cord blood specimen. This gives AmStem a strategic advantage in controlling one of the most efficient and non-controversial supply chain, storage, and delivery systems for stem cells in the world.
Exciting New Treatments
1. AmStem will be generating and monitoring new, improved Clinical Trials to validate and build upon the early successes of Histostem, which has an established pipeline of promising treatments that have already been tested on real patients, including many that are patented in Korea.
2. AmStem will focus on developing a novel Hair Restoration clinical trial, using a method that has already been applied for, and is imminently pending a major U.S. Patent.
3. Histostem is the only company in the world to have full KFDA approval to use its cord blood derived stem cells directly for the treatment of disease. Clinical trials have been in progress for over 2 years to treat intractable conditions such as Buerger’s Disease, Alzheimer’s and Liver Cirrhosis, as well as Diabetes Mellitus, Hair Restoration and ALS.
"Stock listing on a national exchange"
CytoSorbents Goals and Milestones 2010-12
page 33
http://www.cytosorbents.com/pdf/CytoSorbents_Rodman_Presentation_2010.pdf
Seems that the ask is moving up.
CSKH news out! Could go +150-200% easy
"There are approximately 150,000 solar energy systems currently installed in the United States and more than 250,000 in Europe all needing reliable tracking options,"added Green. "We estimate that, with the many benefits of the XTRAX®system, we will be able to secure a minimum of a 25 percent share of this growing market. With the solar energy markets in Asia and Australia growing at an exponential rate the market for the XTRAX® is unlimited."
http://www.free-press-release.com/news-brookville-capital-partners-clear-skies-solar-inc-announced-the-successful-completion-of-field-testing-on-its-patented-xtrax-solar-energy-monitor-1285628856.html
"Field tests have indicated successful calibration of units and show that the XTRAX® unit will provide the best performance in energy systems monitoring at the best value for both solar energy customers and the carbon credit aggregators."
The XTRAX® program is the first of its kind to handle the trading of carbon credits and its comprehensive billing procedures. Currently, energy production from sub 100 kilowatt solar installations are only estimated, leaving carbon credit aggregators with unverified production values that can result in substantial financial losses. With XTRAX®, production values can be guaranteed within plus or minus less than 1 percent, taking any uncertainties out of the equation.
With firmware development, software development and sophisticated programming all completed in-house, XTRAX® will lead the way to a new era of energy production tracking and will ensure that solar systems are working at optimal levels at all times.
The installed XTRAX® units will cost approximately $100 and will come with multi-year contracts with monthly charges at $25 per month, a fee that will be completely offset by the value of the carbon credits that the user receives. "Now that we have successfully calibrated all versions, we will soon be seeking industry certification, which will include the testing and qualification of our proprietary Clear Coil current sensor," said Green.
http://www.free-press-release.com/news-brookville-capital-partners-clear-skies-solar-inc-announced-the-successful-completion-of-field-testing-on-its-patented-xtrax-solar-energy-monitor-1285628856.html
Lucky Picks of The Day: (OTCBB:CSKH)
MINEOLA, N.Y., Sep 30, 2010 -- Clear Skies Solar, Inc. (CSS) (OTCBB:CSKH), a full-service renewable energy provider to commercial, industrial and agricultural clients, today announced it has received notice from Met Laboratories, an independent testing facility, that the XTRAX(R) units tested were verified to be operating within meter industry guidelines.
The first seven ANSI tests
relating to accuracy and continuity have shown compliance with ANSI standards. Carbon 612's own testing showed a margin of error of less than one half of one percent, making it valuable for accurate monetization of Renewable Energy Credits, PPA providers, utility and industrial sub-monitoring.
The US patent for XTRAX is held by Carbon 612, which is a majority-owned subsidiary of CSS. With the ability to monitor with a high degree of accuracy and a low installed cost, XTRAX is designed for the mass markets throughout the US and elsewhere, and its patent applications are pending in European and Chinese markets.
"The XTRAX hardware, firmware and our server-based software
was developed in-house with plans on entering into several additional renewable-based markets. By expanding the Carbon 612 recurring-revenue model, we will be ensuring that our market positioning and growth will be well-rounded," said Ezra Green, CEO of Clear Skies Solar.
Continuing, Mr. Green said: "We are pleased that we are able to announce the progress made with our technology and look forward to bringing XTRAX, the next generation of comprehensive energy tracking, to the mass markets."
http://www.tradingmarkets.com/news/press-release/cskh_cskhe_mcve_mcve_tegy_tegy_shamrockstocks-com-lucky-picks-of-the-day-otcbb-cskh-otcbb-mcve-otcbb-tegy--1200955.html
This stock could go + 150% easily on this news alone.
I've just bought 20k at 0.026
What is the bid and ask?
You're welcome.
allright... just teasing... good luck with this stock...
it seems to have a lot of potential. It's just that I am almost out of money now, so I have to pass on this one.
Thanks for bringing us the bad news. No need to buy shares now you say.
Update: CytoSorbents Executive Summary - Sept 2010:
http://02c390e.netsolhost.com/pdf/CytoSorbents_Sept_2010_Exec_Summary.pdf
Very interesting.
I haven't lost anything b/c I haven't sold anything. I hold 12,5M shares and call me crazy, but I think we should still have hope.
I agree. I have a small position in this stock. You could call me "long and weak" (instead of long and strong).
Ok. I didn't know that. Good for them. That's the way to do business in China.
I think the Chinese government and the government from Mongolia will prefer the Welwind's - Yatu cooperation developping wind turbines above GE. Yatu is a Chinese company and General Electric is solely American. IMO
To be continued...
My position: Long
One advice: hold your shares, buy more because this stock yells for going to and over the dollar.
Their board of advisors and expert is like the dream team basketball at summer Olympics in Barcelona starring Magic Jackson, Michael Jordan, Scotty Pippen, Karl Malone, ...
Overwhelming, epic, huge.
Shareholders who are long don't bother writing down their opinion on these message boards. It's all I can say.
I have my shares locked down. I will hold all my shares between 5 and 10 years.
Great news. Moreover I like these parts:
"We are very pleased to have attained this key milestone. ISO 13485 certification confirms that our manufacturing and quality systems meet the same high standards required of other major US medical device companies selling into Europe. Of the possible options, Full Quality Systems certification is the most stringent and efficient route to CE Mark approval for CytoSorb™ and other future CytoSorbents products. When coupled with CE Mark approval, ISO 13485 certification will allow CytoSorbents to commercialize its products in the E.U. market and other countries that recognize the ISO 13485 and CE Mark standards."
For the contest: AMST
I'll start buying when the declination stops. So I decide to wait (a week, two weeks, ...). It will take a long time to reach that 52wk high again when this stock wiil have finally botommed.
Congratulations to the 2010 CFO of the Year Finalists!
The NJBIZ CFO of the Year awards program celebrates New Jersey’s financial executives at all levels who contribute to the success of New Jersey’s economic growth and stability.
Join us on Tuesday, October 26, 2010 as we honor these outstanding finalists and announce the winners in each category during an awards breakfast at the Palace at Somerset Park in Somerset, NJ. :
Date: October 26, 2010
Time: 8:00am to 10:30am
Location: The Palace at Somerset Park, Somerset, NJ
Registration cost: $60.00
The 2010 CFO of the Year Finalists!
Public Company
Luke M. Beshar
NPS Pharmaceuticals
Silvano Dall'Asta
Siemens Corporate Research, a division of Siemens Corporation
David Lamadrid
CytoSorbents Corporation
Kevin T. Scull, CMA, CPA
Wayside Technology Group, Inc.
Michael A. Stivala
Suburban Propane Partners, LP
link:
http://www.njbiz.com/component/redevent/details/35-cfo-of-the-year-awards?pop=1&tmpl=component
Just expressing my opinion. GLTA
There is no certain bottom: 0.002 or 0.02 or 0.04. Everything is possible, but IMO it would be stupid to buy when it has dropped more than 50%. Because when you buy in a descending line, chances are high that pps will drop even more.
My opinion is to share your opinion.
I agree. It would be stupid to buy shares at this moment when you can clearly see a downtrend. It's better to buy shares after the bottom is reached and share price is rising than to buy when share price could possibly be dropping another 80%.
Calm before the storm at PPS.080-0.090.
Possible updates which could induce the storm this year:
1. Partnerships, institutional investing
2. 80patients enrollment news
3. 100patients enrollment news
4. the army which financially supports (bioterror~sepsis)
When will news come out? Could be tomorrow, could be next week, ... In any case it should be soon.
Don't know,but we'll close between $.50-$1 at the end of the year.
Water purification is the challenge of this century.
Congratulations everybody. My bid remains 0.021 but it doesn't look it's going to be filled today.
Happy trading guys.
And what if there were other lawsuits coming, what if the mining exploration results weren't that astonishing as first thought, what if ...?
People who were in at +0.10 already lost 0.04dollar/share now. Don't bother me, bother the stock price.